Nayar Laboratory
Research. Teaching. Public Health.
A major reason people die of cancer is because their cancer has become resistant to targeted therapies (i.e. drugs that target a specific pro-growth molecule or pathway).
The Nayar Laboratory at Johns Hopkins University is dedicated to the study of therapeutic resistance in breast and ovarian cancer. Equally important to our mission is the training of the next generation of cancer researchers. Our goal is to lessen the public health burden of cancer through science.
Research
Therapeutic resistance in breast and ovarian cancer
The Nayar laboratory is focused on the biology of therapeutic resistance in breast and ovarian cancer. Dr. Nayar recently identified a subset of breast cancer that becomes resistant to targeted therapy by acquiring mutations in other oncogenes. The laboratory aims to understand the underlying mechanism(s) by which a tumor becomes resistant to targeted therapy.
Transcriptional control of resistance
See: Jeselsohn et al., Cancer Cell 2018
We use genomic footprinting technologies to study transcriptional networks in endocrine resistant breast cancer.
Oncogene variant-to-function
We employ deep mutational scanning and functional genomic technologies to comprehensively characterize mutations in important oncogenes in breast and gynecological cancers.
Therapeutic vulnerabilities of resistant breast cancer
We employ whole-genome screening technologies to identify novel biological dependencies and therapeutic vulnerabilities in targeted therapy-resistant breast cancer.
Inflammation and breast cancer
See: No background readings available
We are exploring the roles of inflammatory signaling in targeted therapy-resistant breast cancer.
Contact Us
Please contact us directly for job enquiries or other questions.